Gene Hung

USPTO Granted Patents = 31 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 176(Granted Patents)

Location History:

Carlsbad, CA (US) (2014 - 2022)
San Diego, CA (US) (2014 - 2024)
San Francisco, CA (US) (2023 - 2024)

Company Filing History:

13 out of 270

Ionis Pharmaceuticals, Inc.

patents

4 out of 1,035

Isis Pharmaceuticals, Inc.

Cold Spring Harbor Laboratory

University of Utah Research Foundation

patents

7. 2 out of 2

Xizang Haisco Pharmaceutical Co., Ltd.

patents

8. 2 out of 8

Sichuan Haisco Pharmaceutical Co., Ltd.

patents

9. 2 out of 2

Fronthera U.S. Pharmaceuticals LLC

patents

10. 1 out of 53

Chdi Foundation, Inc.

patents

11. 1 out of 1

Esker Therapeutics, Inc.

patent

12. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2025

where 'Filed Patents' based on already Granted Patents

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12358899 - Thyroid hormone receptor agonists and uses thereof (2025-07-15),

2. 12351572 - Substituted 1,2,4-triazoles as TYK2 inhibitors (2025-07-08),

3. 12297431 - Modulation of huntingtin expression (2025-05-13),

4. 12060343 - Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors (2024-08-13),

5. 12006306 - Substituted pyridazines as TYK2 inhibitors (2024-06-11),

6. 11964964 - Thyroid hormone receptor agonists and uses thereof (2024-04-23),

7. 11959080 - Methods and compositions for inhibiting PMP22 expression (2024-04-16),

8. 11834660 - Compositions for modulating Ataxin 2 expression (2023-12-05),

9. 11731956 - Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors (2023-08-22),

10. 11421231 - Modulation of Huntington expression (2022-08-23),

11. 11136577 - Methods and compositions for inhibiting PMP22 expression (2021-10-05),

12. 11053219 - Substituted pyridines as TYK2 inhibitors (2021-07-06),

13. 11040972 - Autotaxin inhibitors and uses thereof (2021-06-22),

14. 11034671 - Apoptosis signal-regulating kinase inhibitors and uses thereof (2021-06-15),

15. 10837016 - Modulation of huntingtin expression (2020-11-17),

Title: Gene Hung: Innovator in Thyroid Hormone Research

Introduction

Gene Hung, an accomplished inventor based in San Diego, California, has made significant contributions to the field of medical research with a focus on thyroid hormone-related therapies. With an impressive portfolio of 25 patents, Gene continues to advance our understanding of thyroid hormone receptor activity and its implications for treating various medical conditions.

Latest Patents

Among Gene's latest patents are groundbreaking innovations in the treatment of diseases associated with thyroid hormone receptor activity. One notable patent details methods and compositions for utilizing thyroid hormone receptor agonists to treat conditions, diseases, or disorders linked to thyroid hormone receptor functionality. Additionally, he has developed methods and compounds for inhibiting PMP22 expression, providing potential treatments for diseases associated with this specific protein.

Career Highlights

Gene Hung has had a prominent career in the pharmaceutical industry, working with renowned organizations such as Ionis Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. His research and innovations have earned him respect and recognition within the field of medical sciences, particularly in areas focused on endocrine health.

Collaborations

Throughout his career, Gene has collaborated with notable professionals including C Frank Bennett and Susan M Freier. These partnerships have facilitated the successful development of innovative treatments and have contributed to the advancement of research in hormone receptor therapies.

Conclusion

Gene Hung stands out as a pivotal figure in the field of medical research, particularly with his focus on thyroid hormone receptor activity. With a strong patent portfolio that reflects his commitment to innovation, he continues to make strides in developing therapies that address crucial health issues. His work exemplifies the importance of collaboration and innovation in the advancement of medical science.

This text is generated by artificial intelligence and may not be accurate.